Currently, Athira Pharma Inc [ATHA] is trading at $0.34, up 12.92%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ATHA shares have gain 12.21% over the last week, with a monthly amount glided 12.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Athira Pharma Inc [NASDAQ: ATHA] stock has seen the most recent analyst activity on September 19, 2024, when Mizuho downgraded its rating to a Neutral and also revised its price target to $0.50 from $5. Previously, Rodman & Renshaw downgraded its rating to Neutral on September 04, 2024. On September 04, 2024, downgrade downgraded it’s rating to Mkt Perform. BTIG Research downgraded its rating to a Neutral. Rodman & Renshaw initiated its recommendation with a Buy and recommended $22 as its price target on August 19, 2024. JMP Securities upgraded its rating to Mkt Outperform for this stock on October 17, 2022, but kept the price target unchanged to $20. In a note dated July 07, 2022, Mizuho initiated an Buy rating and provided a target price of $6 on this stock.
This stock has fluctuated between a low of $0.22 and a high of $3.67 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $18 within the next 12 months. Athira Pharma Inc [NASDAQ: ATHA] shares were valued at $0.34 at the most recent close of the market. An investor can expect a potential return of 5194.12% based on the average ATHA price forecast.
Analyzing the ATHA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -1.83, Equity is -1.43 and Total Capital is -2.18. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.3067 points at the first support level, and at 0.2733 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.3617, and for the 2nd resistance point, it is at 0.3833.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Athira Pharma Inc [NASDAQ:ATHA] is 7.26. Also, the Quick Ratio is 7.26, while the Cash Ratio stands at 4.81.
Transactions by insiders
Recent insider trading involved CHURCH KEVIN, CHIEF SCIENTIFIC OFFICER, that happened on Jul 01 ’25 when 8526.0 shares were sold. President and CEO, Litton Mark James completed a deal on Jul 01 ’25 to sell 25123.0 shares. Meanwhile, CHIEF MEDICAL OFFICER San Martin Javier sold 10842.0 shares on Jul 01 ’25.
